AbCellera Biologics News

KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksMay 16 14:25

Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71

Yahoo FinanceMay 10 18:16

Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)

TipRanksMay 10 13:52

AbCellera Biologics Is Maintained at Overweight by Keybanc

AbCellera Biologics Is Maintained at Overweight by Keybanc

Dow JonesMay 9 02:29

AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc

AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc

Dow JonesMay 9 02:29

Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.

Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.

Zhitong FinanceMay 9 02:20

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics with a Overweight and lowers the price target from $8 to $7.

Analyst UpgradesMay 9 02:18

AbCellera Biologics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 83.73% Keybanc $8 → $7 Maintains Overweight 02/22/2024 — Benchmark Upgrades Hold → Buy 02/21/2

BenzingaMay 9 02:17

Earnings Call Summary | AbCellera Biologics(ABCL.US) Q1 2024 Earnings Conference

The following is a summary of the AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript:Financial Performance:AbCellera reported Q1 2024 revenue of $10 million, primarily from research fees

Futu NewsMay 8 23:36 · Conference Call

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 8 23:03

Analysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)

TipRanksMay 8 15:10

AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates

Yahoo FinanceMay 8 06:01

AbCellera Biologics | 10-Q: Quarterly report

Futu NewsMay 8 04:54 · Announcements

AbCellera Biologics Reviews Q1 Earnings With Corporate Presentation

TipRanksMay 8 04:33

Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q1 Revenue $10M, Vs. Street Est of $10.9M

04:25 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q1 Revenue $10M, vs. Street Est of $10.9M

MT NewswiresMay 8 04:25

AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 m

BenzingaMay 8 04:13

Press Release: AbCellera Reports Q1 2024 Business Results

AbCellera Reports Q1 2024 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)--May 07, 2024-- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All

Dow JonesMay 8 04:05

AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation

Seeking AlphaMay 1 23:44

Institutional Owners May Consider Drastic Measures as AbCellera Biologics Inc.'s (NASDAQ:ABCL) Recent US$91m Drop Adds to Long-term Losses

Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders

Simply Wall StApr 22 18:42

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Business WireApr 9 00:05